Refine
Year of publication
Document Type
- Preprint (689)
- Article (460)
- Conference Proceeding (4)
- Report (3)
- Review (1)
- Working Paper (1)
Has Fulltext
- yes (1158)
Is part of the Bibliography
- no (1158)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Epilepsy (3)
- Frieden (3)
- Friedenskonferenz (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- MSC (3)
- MSC2013 (3)
- Prostate cancer (3)
- Sicherheitskonferenz (3)
- TAVI (3)
- pp collisions (3)
- radical prostatectomy (3)
- security conference (3)
- Beauty production (2)
- Bipolar disorder (2)
- Charm physics (2)
- Diagnostic markers (2)
- Elliptic flow (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Heavy-ion collisions (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Machine learning (2)
- München (2)
- Oncology (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- Seizure (2)
- Single electrons (2)
- aortic stenosis (2)
- biomarker (2)
- functional outcome (2)
- pelvic packing (2)
- penile cancer (2)
- prostate cancer (2)
- targeted therapy (2)
- 900 GeV (1)
- ACE inhibitor (1)
- AIS (1)
- AKT (1)
- ALICE detector (1)
- AT1 receptor antagonist (1)
- ATM (1)
- Accelerators & Beams (1)
- Accelerators & storage rings (1)
- Alcohol consumption (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- Aortic stenosis (1)
- Artesunate (1)
- Artificial Intelligence (1)
- Artificial intelligence (1)
- Atomic & molecular beams (1)
- Atomic and Molecular Physics (1)
- Atomic, Molecular & Optical (1)
- Awareness campaign (1)
- B-slope (1)
- BESIII (1)
- BPDCN (1)
- BPH (1)
- Beam loss (1)
- Benutzeroberfläche (1)
- Biodiversity Data (1)
- Biomarker (1)
- Biomarkers (1)
- Biomedical engineering (1)
- Biomonitoring (1)
- Blood pressure (1)
- Bone cement implantation syndrome (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Breast cancer (1)
- C-clamp (1)
- CDKN2A (1)
- CRPC (1)
- CT (1)
- CVID (1)
- Cancer (1)
- Cancer check up (1)
- Cancer detection and diagnosis (1)
- Cell-to-Cell Spread (1)
- Centrality Class (1)
- Centrality Selection (1)
- Cerebral oxygen saturation (1)
- Cerebrovascular disorders (1)
- Charge-transfer collisions (1)
- Charm quark spatial diffusion coefficient (1)
- Children (1)
- Circadian (1)
- Circular accelerators (1)
- Clinical study (1)
- Coalescence (1)
- Collective Flow, (1)
- Collectivity (1)
- Comparison with QCD (1)
- Computerlinguistik (1)
- Conservation (1)
- Conservation biogeography (1)
- Correlation (1)
- Costs (1)
- Critical point (1)
- Deuteron production (1)
- Diagnostic differentiation (1)
- Diffraction (1)
- Digitization (1)
- Elastic scattering (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Electroweak interaction (1)
- Esophageal adenocarcinoma (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus (1)
- Eyes (1)
- FFLU (1)
- Falciparum (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Functional outcomes (1)
- FungiScope® registry (1)
- GFAP (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- Genetic causes of cancer (1)
- Genetic testing (1)
- Genetic wildlife monitoring (1)
- Genetics (1)
- Genetics research (1)
- German PID-NET registry (1)
- Glaucoma (1)
- Gleason Grade Group (1)
- HBT (1)
- HCC (1)
- HNSCC (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hair sampling (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Herbaria (1)
- Higher moments (1)
- Hip hemiarthroplasty (1)
- Histology (1)
- HoLEP (1)
- Human genetics (1)
- ICU (1)
- IL-10 (1)
- IL-6 (1)
- ISS (1)
- IgG substitution therapy (1)
- Inclusive spectra (1)
- Initial state radiation (1)
- Injury Severity Score (ISS) (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Invasive fungal infections (1)
- Ionisation energy loss (1)
- Issue 96 (1)
- Jet Physics (1)
- Jet Substructure (1)
- KRAS (1)
- Lee-type (1)
- Local therapy (1)
- Lomentospora prolificans (1)
- Low & intermediate-energy accelerators (1)
- Lure sticks (1)
- MRI (1)
- MTOR inhibitor (1)
- Malaria (1)
- Material budget (1)
- Medicine (1)
- Metastasis-directed therapy (1)
- Mid-rapidity (1)
- MinION (1)
- Minimum Bias (1)
- Mitochondria (1)
- Monte Carlo (1)
- Morphometry (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiparametric MRI (1)
- NIRS (1)
- NRAS (1)
- NSE (1)
- NVBP (1)
- Nerve fibers (1)
- Neural network (1)
- Noninferiority (1)
- Noninvasive genetic sampling (1)
- Nuclear astrophysics (1)
- Nuclear modification factor (1)
- Nuclear physics of explosive environments (1)
- Nuclear reactions (1)
- Oligometastatic (1)
- Outcome (1)
- Ovarian cancer (1)
- PID prevalence (1)
- PSA screening (1)
- PSA-Screening (1)
- PYTHIA (1)
- Palacos reaction (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Pediatric patients (1)
- Percutaneous (1)
- Photon counting (1)
- Plasmodium (1)
- Pneumonia (1)
- Preclinical research (1)
- Prediction (1)
- Predictive markers (1)
- Preventive medicine (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Proteins (1)
- Proteomics (1)
- Proton (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Prävention (1)
- Psychiatry (1)
- Quantitative features (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Quinine (1)
- Radiative capture (1)
- Radical prostatectomy (1)
- Radiomics (1)
- Radiotherapy (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Renal lesions (1)
- Renal replacement therapy (1)
- Research Infrastructure (1)
- Resolution Parameter (1)
- Rhabdomyoma (1)
- Risk factors (1)
- S100b (1)
- SARS-CoV-2 (1)
- SNORD95 (1)
- SR-BI (1)
- SVR (1)
- Scedosporium spp. (1)
- Seasonal variation (1)
- Semantics (1)
- Severe malaria (1)
- Shear viscosity (1)
- Single muons (1)
- Sociodemographic characteristics (1)
- Solar insolation (1)
- Statistical analysis (1)
- Stroke (1)
- Subependymal giant cell astrocytoma (1)
- Suchmaschine (1)
- Suicide (1)
- Sunlight (1)
- Surgery (1)
- Surgical oncology (1)
- Systematic Uncertainty (1)
- Systemic therapy (1)
- TACE (1)
- TILs (1)
- TR (1)
- TSC (1)
- TURP (1)
- Taxonomy (1)
- Thermal model (1)
- Thoracic trauma (1)
- Time Projection Chamber (1)
- Tinnitus (1)
- Tomography (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Urinary continence (1)
- Urinary incontinence (1)
- VISTA (1)
- Valvular cardiomyopathy (1)
- Vector Boson Production (1)
- Voriconazole (1)
- Vorsorgeuntersuchung (1)
- Xenon-based gas mixture (1)
- adverse events (1)
- algorithm (1)
- allogeneic stem cell transplant (1)
- angiography (1)
- antibiotic resistance (1)
- apex (1)
- assembly (1)
- atherosclerosis (1)
- biopsy cores (1)
- bladder neck stenosis (1)
- blastic plasmacytoid dendritic cell neoplasm (1)
- bloodstream infections (1)
- bundle (1)
- c-MET (1)
- cabozantinib (1)
- cardiac events (1)
- cardiac magnetic resonance (1)
- castration resistance (1)
- cell barrier integrity (1)
- cell lines (1)
- cetuximab (1)
- chemotherapy (1)
- clinical stage (1)
- complications (1)
- confirmatory factor analysis (1)
- coronary calcium (1)
- coronary computed-tomography angiography (CCTA) (1)
- coronary plaques (1)
- cuticular hydrocarbons (1)
- dE/dx (1)
- decision tree (1)
- delirium (1)
- desaturase (1)
- detector (1)
- direct-acting antivirals (1)
- dislocation (1)
- e-scooter (1)
- early tumor stages (1)
- electric scooter (1)
- elongase (1)
- embolization (1)
- endourology (1)
- experimental results (1)
- external fixation (1)
- fixed-links modeling (1)
- fluid intelligence (1)
- formalin-fixed and paraffin-embedded tissue (FFPE) (1)
- formicine (1)
- fracture (1)
- head-and-neck cancer (1)
- heavy ion experiments (1)
- hemodynamic instability (1)
- hemorrhage (1)
- hepatic fibrosis (1)
- hepatic stellate cells (1)
- hepatitis C virus (1)
- hepatocellular cancer (1)
- histone deacetylase 5 (1)
- hospital length of stay (1)
- in vitro models (1)
- incontinence (1)
- insulin resistance (1)
- intensive care admission and mortality (1)
- lactate (1)
- laser-capture microdissection (1)
- leukemia (1)
- lung cancer (1)
- mTOR (1)
- mTOR inhibitor (1)
- management (1)
- marker (1)
- membranous urethra (1)
- metastasis (1)
- metastatic prostate cancer (1)
- miR-142-3p (1)
- miRNA (1)
- mid-term urinary continence (1)
- mortality (1)
- multiparametric magnetic resonance imaging (1)
- multiple trauma (1)
- mutually exclusive mutations (1)
- myocardial fibrosis (1)
- myocyte enhancer factor 2 (1)
- nerve-sparing surgery (1)
- next generation sequencing (1)
- nocardia (1)
- nocardiosis (1)
- oxLDL (1)
- p21-activated kinase 2 (1)
- pad-test (1)
- patient-reported outcomes (1)
- pediatric patients (1)
- pelvic injury (1)
- pelvic ring fracture (1)
- plasma (1)
- polytrauma (1)
- posttraumatic inflammation (1)
- prediction (1)
- prevention (1)
- primary immunodeficiency (PID) (1)
- prognosis (1)
- prostaglandin E2 (1)
- protein kinase D (1)
- proteomics (1)
- pulmonary nocardiosis (1)
- quantitative mass spectrometry (1)
- quark gluon plasma (1)
- re-irradiation (1)
- recurrent mutations (1)
- registry for primary immunodeficiency (1)
- resistant cell lines (1)
- risk group (1)
- risk prediction (1)
- scar (1)
- serum (1)
- solid tumors (1)
- sorafenib (1)
- spectra (1)
- spike-in SILAC (1)
- spine (1)
- squamous cell carcinoma (1)
- stage migration (1)
- steatosis (1)
- stroke (1)
- surgery (1)
- survival (1)
- tivantinib (1)
- traffic accident (1)
- transportation (1)
- traumatic brain injury (1)
- traumatic brain injury (TBI) (1)
- traumaticbraininjury(TBI) (1)
- treatment (1)
- urinary incontinence (1)
- vertebroplasty (1)
- working memory capacity (1)
- x-ray techniques (1)
- Öffentlichkeit (1)
- √sN N = 2.76 TeV (1)
- fibrogenesis (1)
Institute
Background: To test the impact of urethral sphincter length (USL) and anatomic variants of prostatic apex (Lee-type classification) in preoperative multiparametric magnet resonance imaging (mpMRI) on mid-term continence in prostate cancer patients treated with radical prostatectomy (RP). Methods: We relied on an institutional tertiary-care database to identify patients who underwent RP between 03/2018 and 12/2019 with preoperative mpMRI and data available on mid-term (>6 months post-surgery) urinary continence, defined as usage 0/1 (-safety) pad/24 h. Univariable and multivariable logistic regression models were fitted to test for predictor status of USL and prostatic apex variants, defined in mpMRI measurements. Results: Of 68 eligible patients, rate of mid-term urinary continence was 81% (n = 55). Median coronal (15.1 vs. 12.5 mm) and sagittal (15.4 vs. 11.1 mm) USL were longer in patients reporting urinary continence in mid-term follow-up (both p < 0.01). No difference was recorded for prostatic apex variants distribution (Lee-type) between continent vs. incontinent patients (p = 0.4). In separate multivariable logistic regression models, coronal (odds ratio (OR): 1.35) and sagittal (OR: 1.67) USL, but not Lee-type, were independent predictors for mid-term continence. Conclusion: USL, but not apex anatomy, in preoperative mpMRI was associated with higher rates of urinary continence at mid-term follow-up.
Background: Epileptic seizures are common clinical features in patients with acute subdural hematoma (aSDH); however, diagnostic feasibility and therapeutic monitoring remain limited. Surface electroencephalography (EEG) is the major diagnostic tool for the detection of seizures but it might be not sensitive enough to detect all subclinical or nonconvulsive seizures or status epilepticus. Therefore, we have planned a clinical trial to evaluate a novel treatment modality by perioperatively implanting subdural EEG electrodes to diagnose seizures; we will then treat the seizures under therapeutic monitoring and analyze the clinical benefit.
Methods: In a prospective nonrandomized trial, we aim to include 110 patients with aSDH. Only patients undergoing surgical removal of aSDH will be included; one arm will be treated according to the guidelines of the Brain Trauma Foundation, while the other arm will additionally receive a subdural grid electrode. The study's primary outcome is the comparison of incidence of seizures and time-to-seizure between the interventional and control arms. Invasive therapeutic monitoring will guide treatment with antiseizure drugs (ASDs). The secondary outcome will be the functional outcome for both groups as assessed via the Glasgow Outcome Scale and modified Rankin Scale both at discharge and during 6 months of follow-up. The tertiary outcome will be the evaluation of chronic epilepsy within 2-4 years of follow-up.
Discussion: The implantation of a subdural EEG grid electrode in patients with aSDH is expected to be effective in diagnosing seizures in a timely manner, facilitating treatment with ASDs and monitoring of treatment success. Moreover, the occurrence of epileptiform discharges prior to the manifestation of seizure patterns could be evaluated in order to identify high-risk patients who might benefit from prophylactic treatment with ASDs.
Trial registration: ClinicalTrials.gov identifier no. NCT04211233.
Simple Summary: Penile cancer is a rare but aggressive malignancy characterized by rapid tumor growth as well as prompt metastasis in groin lymphatics. While localized diseases can be successfully cured by surgery in most cases, no truly effective treatment options have been established for metastatic diseases as of yet. In the current investigation, we assessed the value of selected members of the PI3K/mTOR/AKT pathway to serve as tumor markers or therapeutic targets for this disease. Higher expression of AKT was significantly more prevalent in high-grade tumors and independently predictive of the worse survival parameters, while increased expression of pmTOR was associated with an inferior prognosis as well. Treatment with the pan-AKT inhibitor capivasertib in PeCa cell lines induced significant reduction of cell viability and movement capacity. These findings might aid in the understanding of the molecular tumor background as well as development of novel treatment options for advanced penile cancer.
Abstract: The PI3K/mTOR/AKT pathway might represent an intriguing option for treatment of penile cancer (PeCa). We aimed to assess whether members of this pathway might serve as biomarkers and targets for systemic therapy. Tissue of primary cancer from treatment-naïve PeCa patients was used for tissue microarray analysis. Immunohistochemical staining was performed with antibodies against AKT, pAKT, mTOR, pmTOR, pS6, pPRAS, p4EBP1, S6K1 and pp70S6K. Protein expression was correlated with clinicopathological characteristics as well as overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS) and metastasis-free survival (MFS). AKT inhibition was tested in two primarily established, treatment-naïve PeCa cell lines by treatment with capivasertib and analysis of cell viability and chemotaxis. A total of 76 patients surgically treated for invasive PeCa were included. Higher expression of AKT was significantly more prevalent in high-grade tumors and predictive of DSS and OS in the Kaplan–Meier analysis, and an independent predictor of worse OS and DSS in the multivariate regression analysis. Treatment with pan-AKT inhibitor capivasertib in PeCa cell lines induced a significant downregulation of both total AKT and pAKT as well as decreased cell viability and chemotaxis. Selected protein candidates of the mTOR/AKT signaling pathway demonstrate association with histological and survival parameters of PeCa patients, whereas AKT appears to be the most promising one.
Probably, patients with de novo (synchronous) and recurrent (metachronous) oligometastatic hormone-sensitive prostate cancer have different oncologic outcomes. Thus, we are challenged with different scenarios in clinical practice, where different treatment options may apply. In the last years, several prospective studies have focused on the treatment of patients with de novo oligometastatic hormone-sensitive prostate cancer. Not only the addition of systemic therapeutic treatments, such as chemotherapy with docetaxel, abiraterone, enzalutamide, and apalutamide, next to androgen deprivation therapy, demonstrated to improve outcomes in these patients but also local therapy of the primary has been demonstrated to improve outcomes of low-volume metastatic disease. Next to radiotherapy, also radical prostatectomy has been reported as a feasible and safe treatment option. Additional metastasis-directed therapy in de novo metastatic disease is currently examined by four trials. In the recurrent metastatic setting, less data are available, and it remains uncertain if patients can be treated in the same way as synchronous oligometastatic disease. Metastasis-directed therapy has demonstrated to prolong outcomes, while data on survival are still missing.
Background: Pulmonary nocardiosis (PN) is an uncommon but potentially life-threatening infection. Most of our knowledge is derived from case reports or smaller case series. Recently, increasing PN incidence rates have been reported. We aim to describe the clinical course of and risk factors for PN in four Western European countries and to estimate population-based annual hospitalization rates.
Methods: Retrospective evaluation (1995 to 2011) of the clinical course of and risk factors for PN in patients from 11 hospitals in four European countries (Germany, Austria, Switzerland and The Netherlands). Calculation of population-based estimates of hospitalization rates of PN in Germany (2005 to 2011) using official German nationwide diagnosis-related groups (DRG) hospital statistics.
Results: Forty-three patients fulfilled stringent criteria for proven (n = 8) and probable (n = 35) PN; seven with extrapulmonary dissemination. Within the 43 patients, major PN risk factors were immunocompromising (83.7%) and/or pulmonary (58.1%; in 27.9% as only comorbidity) comorbidities. Median duration of PN targeted therapy was 12 weeks. Distinguished patterns of resistance were observed (imipenem susceptibility: N. farcinica 33.3%; N. asteroides 66.7%). Overall mortality rate was 18.9%; in disseminated PN 50%. Over time, annual PN hospitalization rates remained unchanged at around 0.04/100′000 with the highest rate among men aged 75–84 years (0.24/100′000).
Conclusion: PN is rare, but potentially life-threatening, and mainly affects immunocompromised elder males. Overall annual hospitalization rates remained stable between 2005 and 2011.
Background: Various studies have been made about the most effective and safest type of treatment for vertebral compression fractures (VCFs). Long-term results are needed for qualitative evaluation.
Purpose: The purpose of the study is to evaluate the effectiveness of percutaneous vertebroplasty (PVP) and percutaneous kyphoplasty (PKP) procedures for VCFs.
Materials and Methods: Forty-nine patients who received either PVP or PKP between 2002 and 2015 returned a specially developed questionnaire and were included in a cross-sectional outcome analysis. The questionnaire assessed pain development by use of a visual analog scale (VAS). Imaging data (CT scans) were retrospectively analyzed for identification of cement leakage.
Results: Patients’ VAS scores significantly decreased after treatment (7.0 ± 3.4 => 3.7 ± 3.4), (p < 0.001). The average pain reduction in patients treated with PVP was −3.3 ± 3.8 (p < 0.001) (median −3.5) and −4.0 ± 3.9 (p < 0.001) (median −4.5) in patients treated with PKP. Fifteen Patients (41.7%) receiving PVP and four patients (30.7%) receiving PKP experienced recurrence of pain. Cement leakage occurred in 10 patients (22.73%). Patients with cement leakage showed comparable VAS scores after treatment (6.8 ± 3.5 => 1.4 ± 1.6), (p = 0.008). Thirty-nine patients reported an increase in mobility (79.6%) and 41 patients an improvement in quality of life (83.7%).
Conclusion: Pain reduction by means of PVP or PKP in patients with VCFs was discernible over the period of observation. Percutaneous vertebroplasty and PKP contribute to the desired treatment results. However, the level of low pain may not remain constant.
A wide variety of enzymatic pathways that produce specialized metabolites in bacteria, fungi and plants are known to be encoded in biosynthetic gene clusters. Information about these clusters, pathways and metabolites is currently dispersed throughout the literature, making it difficult to exploit. To facilitate consistent and systematic deposition and retrieval of data on biosynthetic gene clusters, we propose the Minimum Information about a Biosynthetic Gene cluster (MIBiG) data standard.
The charged particle community is looking for techniques exploiting proton interactions instead of X-ray absorption for creating images of human tissue. Due to multiple Coulomb scattering inside the measured object it has shown to be highly non-trivial to achieve sufficient spatial resolution. We present imaging of biological tissue with a proton microscope. This device relies on magnetic optics, distinguishing it from most published proton imaging methods. For these methods reducing the data acquisition time to a clinically acceptable level has turned out to be challenging. In a proton microscope, data acquisition and processing are much simpler. This device even allows imaging in real time. The primary medical application will be image guidance in proton radiosurgery. Proton images demonstrating the potential for this application are presented. Tomographic reconstructions are included to raise awareness of the possibility of high-resolution proton tomography using magneto-optics.
Background: Malaria remains one of the most serious infections for travellers to tropical countries. Due to the lack of harmonized guidelines a large variety of treatment regimens is used in Europe to treat severe malaria.
Methods: The European Network for Tropical Medicine and Travel Health (TropNet) conducted an 8-year, multicentre, observational study to analyse epidemiology, treatment practices and outcomes of severe malaria in its member sites across Europe. Physicians at participating TropNet centres were asked to report pseudonymized retrospective data from all patients treated at their centre for microscopically confirmed severe Plasmodium falciparum malaria according to the 2006 WHO criteria.
Results: From 2006 to 2014 a total of 185 patients with severe malaria treated in 12 European countries were included. Three patients died, resulting in a 28-day survival rate of 98.4%. The majority of infections were acquired in West Africa (109/185, 59%). The proportion of patients treated with intravenous artesunate increased from 27% in 2006 to 60% in 2013. Altogether, 56 different combinations of intravenous and oral drugs were used across 28 study centres. The risk of acute renal failure (36 vs 17% p = 0.04) or cerebral malaria (54 vs 20%, p = 0.001) was significantly higher in patients ≥60 years than in younger patients. Respiratory distress with the need for mechanical ventilation was significantly associated with the risk of death in the study population (13 vs 0%, p = 0.001). Post-artemisinin delayed haemolysis was reported in 19/70 (27%) patients treated with intravenous artesunate.
Conclusion: The majority of patients with severe malaria in this study were tourists or migrants acquiring the infection in West Africa. Intravenous artesunate is increasingly used for treatment of severe malaria in many European treatment centres and can be given safely to European patients with severe malaria. Patients treated with intravenous artesunate should be followed up to detect and manage late haemolytic events.
Immune checkpoint modulation in cancer has been demonstrated as a high-value therapeutic strategy in many tumor entities. VISTA is an immune checkpoint receptor regulating T-cell function. To the best of our knowledge, nothing is known about the expression and prognostic impact of VISTA on tumor infiltrating lymphocytes (TILs) in the tumor microenvironment of esophageal adenocarcinoma (EAC). We analyzed in total 393 EACs within a test-cohort (n = 165) and a validation-cohort (n = 228) using a monoclonal antibody (clone D1L2G). These data were statistically correlated with clinical as well as molecular data. 22.2% of the tumor cohort presented with a VISTA expression on TILs. These patients demonstrated an improved median overall survival compared to patients without VISTA expression (202.2 months vs. 21.6 months; p < 0.0001). The favorable outcome of VISTA positive tumors is significant in the entire cohort but mainly driven by the general better prognosis of T1/T2 tumors. However, in the pT1/2 group, VISTA positive tumors show a tremendous survival benefit compared to VISTA negative tumors revealing real long-term survivors in this particular subgroup. The survival difference is independent of the T-stage. This unique characteristic could influence neoadjuvant therapy concepts for EAC, since a profit of therapy could be reduced in the already favorable subgroup of VISTA positive tumors. VISTA emerges as a prognostic biomarker for long-term survival especially in the group of early TNM-stages. Future studies have to show the relevance of VISTA positive TILs within a tumor concerning response to specific immune checkpoint inhibition.
Background & Aims: NAFLD is a growing health concern. The aim of the Fatty Liver Assessment in Germany (FLAG) study was to assess disease burden and provide data on the standard of care from secondary care. Methods: The FLAG study is an observational real-world study in patients with NAFLD enrolled at 13 centres across Germany. Severity of disease was assessed by non-invasive surrogate scores and data recorded at baseline and 12 months. Results: In this study, 507 patients (mean age 53 years; 47% women) were enrolled. According to fibrosis-4 index, 64%, 26%, and 10% of the patients had no significant fibrosis, indeterminate stage, and advanced fibrosis, respectively. Patients with advanced fibrosis were older, had higher waist circumferences, and higher aspartate aminotransferase and gamma-glutamyltransferase as well as ferritin levels. The prevalence of obesity, arterial hypertension, and type 2 diabetes increased with fibrosis stages. Standard of care included physical exercise >2 times per week in 17% (no significant fibrosis), 19% (indeterminate), and 6% (advanced fibrosis) of patients. Medication with either vitamin E, silymarin, or ursodeoxycholic acid was reported in 5%. Approximately 25% of the patients received nutritional counselling. According to the FibroScan-AST score, 17% of patients presented with progressive non-alcoholic steatohepatitis (n = 107). On follow-up at year 1 (n = 117), weight loss occurred in 47% of patients, of whom 17% lost more than 5% of body weight. In the weight loss group, alanine aminotransferase activities were reduced by 20%. Conclusions: This is the first report on NAFLD from a secondary-care real-world cohort in Germany. Every 10th patient presented with advanced fibrosis at baseline. Management consisted of best supportive care and lifestyle recommendations. The data highlight the urgent need for systematic health agenda in NAFLD patients. Lay summary: FLAG is a real-world cohort study that examined the liver disease burden in secondary and tertiary care. Herein, 10% of patients referred to secondary care for NAFLD exhibited advanced liver disease, whilst 64% had no significant liver scarring. These findings underline the urgent need to define patient referral pathways for suspected liver disease.
The electromagnetic process is studied with the initial-state-radiation technique using 7.5 fb−1 of data collected by the BESIII experiment at seven energy points from 3.773 to 4.600 GeV. The Born cross section and the effective form factor of the proton are measured from the production threshold to 3.0 GeV/ using the invariant-mass spectrum. The ratio of electric and magnetic form factors of the proton is determined from the analysis of the proton-helicity angular distribution.
Relative fractions and phases of the intermediate decays are determined. With the detection efficiency estimated by the results of the amplitude analysis, the branching fraction of Dþ s → K−Kþπþπ0 decay is measured to be ð5.42 0.10stat 0.17systÞ%.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematopoietic malignancy characterized by dismal prognosis and overall poor therapeutic response. Since the biology of BPDCN is barely understood, our study aims to shed light on the genetic make-up of these highly malignant tumors. Using targeted high-coverage massive parallel sequencing, we investigated 50 common cancer genes in 33 BPDCN samples. We detected point mutations in NRAS (27.3% of cases), ATM (21.2%), MET, KRAS, IDH2, KIT (9.1% each), APC and RB1 (6.1% each), as well as in VHL, BRAF, MLH1, TP53 and RET (3% each). Moreover, NRAS, KRAS and ATM mutations were found to be mutually exclusive and we observed recurrent mutations in NRAS, IDH2, APC and ATM. CDKN2A deletions were detected in 27.3% of the cases followed by deletions of RB1 (9.1%), PTEN and TP53 (3% each). The mutual exclusive distribution of some mutations may point to different subgroups of BPDCN whose biological significance remains to be explored.
Whereas the lack of biomarkers in penile cancer (PeCa) impedes the development of efficacious treatment protocols, preliminary evidence suggests that c-MET and associated signaling elements may be dysregulated in this disorder. In the following study, we investigated whether c-MET and associated key molecular elements may have prognostic and therapeutic utility in PeCa. Formalin-fixed, paraffin-embedded tumor tissue from therapy-naïve patients with invasive PeCa was used for tissue microarray (TMA) analysis. Immunohistochemical staining was performed to determine the expression of the proteins c-MET, PPARg, β-catenin, snail, survivin, and n-MYC. In total, 94 PeCa patients with available tumor tissue were included. The median age was 64.9 years. High-grade tumors were present in 23.4%, and high-risk HPV was detected in 25.5%. The median follow-up was 32.5 months. High expression of snail was associated with HPV-positive tumors. Expression of β-catenin was inversely associated with grading. In both univariate COX regression analysis and the log-rank test, an increased expression of PPARg and c-MET was predictive of inferior disease-specific survival (DSS). Moreover, in multivariate analysis, a higher expression of c-MET was independently associated with worse DSS. Blocking c-MET with cabozantinib and tivantinib induced a significant decrease in viability in the primary PeCa cell line UKF-PeC3 isolated from the tumor tissue as well as in cisplatin- and osimertinib-resistant sublines. Strikingly, a higher sensitivity to tivantinib could be detected in the latter, pointing to the promising option of utilizing this agent in the second-line treatment setting.
Background: Prostate cancer is a major health concern in aging men. Paralleling an aging society, prostate cancer prevalence increases emphasizing the need for efcient diagnostic algorithms.
Methods: Retrospectively, 106 prostate tissue samples from 48 patients (mean age,
66 ± 6.6 years) were included in the study. Patients sufered from prostate cancer (n = 38) or benign prostatic hyperplasia (n = 10) and were treated with radical prostatectomy or Holmium laser enucleation of the prostate, respectively. We constructed tissue microarrays (TMAs) comprising representative malignant (n = 38) and benign (n = 68) tissue cores. TMAs were processed to histological slides, stained, digitized and assessed for the applicability of machine learning strategies and open–source tools in diagnosis of prostate cancer. We applied the software QuPath to extract features for shape, stain intensity, and texture of TMA cores for three stainings, H&E, ERG, and PIN-4. Three machine learning algorithms, neural network (NN), support vector machines (SVM), and random forest (RF), were trained and cross-validated with 100 Monte Carlo random splits into 70% training set and 30% test set. We determined AUC values for single color channels, with and without optimization of hyperparameters by exhaustive grid search. We applied recursive feature elimination to feature sets of multiple color transforms.
Results: Mean AUC was above 0.80. PIN-4 stainings yielded higher AUC than H&E and
ERG. For PIN-4 with the color transform saturation, NN, RF, and SVM revealed AUC of 0.93 ± 0.04, 0.91 ± 0.06, and 0.92 ± 0.05, respectively. Optimization of hyperparameters improved the AUC only slightly by 0.01. For H&E, feature selection resulted in no increase of AUC but to an increase of 0.02–0.06 for ERG and PIN-4.
Conclusions: Automated pipelines may be able to discriminate with high accuracy between malignant and benign tissue. We found PIN-4 staining best suited for classifcation. Further bioinformatic analysis of larger data sets would be crucial to evaluate the reliability of automated classifcation methods for clinical practice and to evaluate potential discrimination of aggressiveness of cancer to pave the way to automatic precision medicine.